U.S. markets open in 1 hour 22 minutes
  • S&P Futures

    4,140.50
    +22.50 (+0.55%)
     
  • Dow Futures

    33,787.00
    +163.00 (+0.48%)
     
  • Nasdaq Futures

    13,910.50
    +111.75 (+0.81%)
     
  • Russell 2000 Futures

    2,269.20
    +24.20 (+1.08%)
     
  • Crude Oil

    63.01
    -0.14 (-0.22%)
     
  • Gold

    1,745.40
    +9.10 (+0.52%)
     
  • Silver

    25.52
    +0.00 (+0.00%)
     
  • EUR/USD

    1.1970
    -0.0013 (-0.11%)
     
  • 10-Yr Bond

    1.6380
    0.0000 (0.00%)
     
  • Vix

    16.77
    +0.12 (+0.72%)
     
  • GBP/USD

    1.3794
    +0.0013 (+0.10%)
     
  • USD/JPY

    108.7390
    -0.1880 (-0.17%)
     
  • BTC-USD

    62,605.72
    -1,899.02 (-2.94%)
     
  • CMC Crypto 200

    1,367.12
    -8.66 (-0.63%)
     
  • FTSE 100

    6,969.38
    +29.80 (+0.43%)
     
  • Nikkei 225

    29,642.69
    +21.70 (+0.07%)
     

Glaxo/Innoviva's Trelegy Ellipta Gets FDA Nod for Asthma

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
Zacks Equity Research
·2 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

GlaxoSmithKline plc GSK and partner Innoviva, Inc. INVA announced that the FDA has granted approval to its medicine Trelegy Ellipta for a new asthma indication. The FDA has approved the triple combination once-daily single inhaler as a maintenance treatment of asthma in patients aged 18 years and older who are not adequately treated by a combination of ICS and a LABA.

At present, Trelegy Ellipta, a triple combination therapy of inhaled corticosteroid (“ICS”)/LAMA/LABA (fluticasone furoate/umeclidinium/vilanterol 'FF/UMEC/VI'), is approved to treat chronic obstructive pulmonary disease (“COPD”)

With the approval for the asthma indication, Trelegy becomes the first single inhaler triple therapy approved for the maintenance treatment of both asthma and COPD.

The supplemental new drug application seeking approval for the asthma indication was based on data from the phase III CAPTAIN study, which evaluated Trelegy Ellipta versus Relvar/Breo Ellipta (FF/VI). Data from the study showed that treatment with Trelegy Ellipta led to statistically significant improvement in lung function in asthma patients compared with Relvar/Breo.

GlaxoSmithKline’s shares have declined 15.4% so far this year compared with 0.9% decrease of the industry during the period.

 

Trelegy Ellipta brought in sales of £387 in the first half of 2020, recording growth of 85% at constant exchange rate.

Please note that Theravance Biopharma, Inc. TBPH has an economic interest on the royalties that Glaxo will pay to Innoviva on global sales of Trelegy Ellipta.

We remind investors that AstraZeneca’s AZN triple combination therapy Breztri Aerosphere/PT010 was approved for the treatment of COPD in July.

Glaxo currently carries a Zacks Rank #2 (Buy).You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

These Stocks Are Poised to Soar Past the Pandemic

The COVID-19 outbreak has shifted consumer behavior dramatically, and a handful of high-tech companies have stepped up to keep America running. Right now, investors in these companies have a shot at serious profits. For example, Zoom jumped 108.5% in less than 4 months while most other stocks were sinking.

Our research shows that 5 cutting-edge stocks could skyrocket from the exponential increase in demand for “stay at home” technologies. This could be one of the biggest buying opportunities of this decade, especially for those who get in early.

See the 5 high-tech stocks now>>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
AstraZeneca PLC (AZN) : Free Stock Analysis Report
 
GlaxoSmithKline plc (GSK) : Free Stock Analysis Report
 
Theravance Biopharma, Inc. (TBPH) : Free Stock Analysis Report
 
Innoviva, Inc. (INVA) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research